Introduction {#S1}
============

Microglia cells are the main immunocompetent cells in the brain. They colonize the brain in the early prenatal period ([@B58]), but contrary to other tissue resident macrophages, they remain secluded within the CNS throughout life and self-renew at slow pace ([@B6]). Importantly, the CNS microenvironment significantly shapes the microglia's phenotype, endowing them with specific important homeostatic and supportive brain functions ([@B96]). Should the brain homeostasis be compromised, microglia change their phenotype and initiate a defense program. Thus, under pathological conditions, they adopt reactive states characterized by multiple morphological and functional changes including but not limited to increased phagocytosis and increased expression of receptors, cytokines, chemokines and additional inflammation related molecules ([@B199]).

Alzheimer's disease (AD) classical hallmarks include brain atrophy, extracellular amyloid-beta (Aβ) deposits, intracellular aggregated phosphorylated tau, dystrophic neurites, synapses and neurons loss ([@B12]). The presence of reactive glial cells within the neuritic plaques was described by Alois Alzheimer himself ([@B8]; [@B61]) and further studies identified both reactive astrocytes and microglia in the vicinity of the Aβ deposits ([@B188]). Long considered as a consequence of the pathology, reactive glia and associated neuroinflammation are now regarded as playing key roles in both disease initiation and progression. Indeed, Human genetic studies identified over 25 genetic loci that robustly associate with AD risk ([@B70]; [@B187]). Among them, most of the common (ApoE, Sp1l) or rare (Trem2, Cd33) genetic variants code for proteins that are preferentially or exclusively expressed in microglia. These findings strongly support a causal involvement of microglial cells in AD pathogenesis and generated a strong interest for studying these cells in AD. Yet, the roles of microglia in AD initiation and progression are unclear and heavily debated, with conflicting reports regarding their detrimental or protective contribution to the disease.

In the present review, we have summarized the main findings regarding the role of microglia in AD. Microglia reaction is known to be associated with the acquisition of many immune functions which are triggered by the activation of receptors designed to recognize danger or pathogen associated molecular patterns (DAMPs/PAMPs). Its role is to restore homeostasis and is also associated with the loss or the alteration of homeostatic functions which are important for brain physiological functioning. In the two first parts, we thus provide an overview of the microglial functions and pathways that are known to be altered during AD. We then highlight factors such as mouse models, sex, age whose influence may have been under-examined in assessing the contribution of microglial cells to the disease progression. Finally, we identified new research topics that are likely to foster our understanding of the roles of microglia to AD initiation and progression and may help design more targeted therapeutic strategies.

New Functions for Reactive Microglia in AD {#S2}
==========================================

Neuroinflammation is a common feature of neurodegenerative diseases and inflammatory processes are thus among the most studied microglial functions in AD. Microglia, which represent the main immune cells of the brain, have been shown to play key roles in orchestrating this brain inflammation. In the following section, we are reporting the main microglial processes involved in neuroinflammation ([Figure 1](#F1){ref-type="fig"}, top part). However, more detailed description of these processes can be found in recent reviews that are focusing on these specific points ([@B103]; [@B135]).

![Schematic representation of functions microglial cells can loose and gain in context of AD. Microglia is represented in green associated to amyloid-β deposit in purple and dendritic spines in gray.](fnagi-11-00233-g001){#F1}

Inflammasomes Are Central Hubs for Cytokines Production {#S2.SS1}
-------------------------------------------------------

One of inflammation hallmarks is the release of cytokines. This secretion requires the activation of inducible multiproteic complexes called inflammasomes. Several inflammasomes have been characterized but the most important microglial contributor in pathologies is certainly the NLRP3. It is composed of the sensor protein NLRP3 and the adaptor protein apoptosis associated Speck-like protein (ASC), which contains a caspase recruitment domain. ASC can recruit and activate pro-caspase-1. When stimulated, the complex induces the cleavage of pro-caspase-1 into active caspase-1, which in turn cleaves pro-IL-1β and IL-18 triggering their release in the extracellular space ([@B119]). NLRP3 activation pathway is not fully characterized, but the current view is that NLRP3 activation requires the occurrence of two independent but co-concomitant priming and activation signals ([@B145]).

In the context of AD, IL-1β is known to elicit the secretion of NO and TNFα, promoting the formation of deleterious amyloid plaques and neuronal degeneration ([@B62]). In accordance with these data, frontal cortex from AD patients exhibit an increase of caspase-1 which is correlated with an attenuation of Aβ peptide phagocytosis ([@B22]; [@B76]). Likewise, genetic deletion of NLRP3 in mice with familiar AD associated mutation reduces the level of IL-1β and Aβ deposits, and correlates with positive impacts on synaptic dysfunction and cognitive performances ([@B76]).

Other members of the caspase family are also involved in AD pathology. Interestingly, the activity of caspase-3 prematurely increases in hippocampal neurons in an AD mouse model ([@B37]). Similarly, in samples from AD patients, caspase-8 and -3 are upregulated in cortical microglia ([@B22]). Microglial caspase-3 around amyloid plaques also present a cytosolic location, suggesting a non-apoptotic role of caspases in AD ([@B22]). Such evidence has also been described in others degenerative models such as brain ischemia, in which reactive astrocytes and microglia express cytoplasmic non-apoptotic caspase-3 ([@B193]). This non-nuclear localization could be involved in cytoplasmic rearrangement and modifications of cell populations surrounding lesions. Although it is undeniable that caspase signaling is crucial in the development of AD, the delay of activation and the pathway downstream of each of them need to be clarified.

The Complement System, the Microglial Way of Eating Synapses? {#S2.SS2}
-------------------------------------------------------------

The complement pathway is part of the innate immune system and mediates the recognition and elimination of pathogens and cellular debris. It is involved in many physiological and pathological functions throughout life, including activity-dependent synapse elimination during development ([@B158]). In AD, reactivation of this pathway by Aβ deposits has been associated with synapse loss.

The complement cascade is composed of a large panel of mediators including C1q and C3 complex proteins which can be activated by three different pathways, all of which are capable of triggering phagocytosis ([@B171]). In the CNS, complement proteins are expressed in neurons and glial cells, although microglia and astrocytes are the major sources of complement. Particularly, microglia expressed high level of C1q and CR3 ([@B185]) and microglial CR3 have been shown to be crucial in synapse pruning during development ([@B158]).

In AD context, patients showed elevated CSF concentrations of C3 and CR1, pointing out an alteration of complement system in the pathology ([@B36]). The complement has been associated with Aβ but it is not clear whether it is protective or detrimental. Indeed, some studies reported that complement inhibition or deficiency results in accelerated amyloid pathology ([@B200]; [@B116]) and that C3 along with CR3 contribute to Aβ phagocytosis ([@B53]). On the other hand, other studies pointed out that elimination and modulation of microglial CR3 decrease Aβ level ([@B35]) and C3 antagonist ameliorates plaque load ([@B110]). Further studies are thus required to better understand the role of complement in Aβ pathology.

As AD is marked by an important synapse loss, questions have been raised on whether the complement could mediate such synapse elimination. [@B50] demonstrated that C1q deficiency in an AD mouse model partly restores synapse integrity pointing out a role of the complement system in AD. More recently, works from Hong et al. demonstrated that microglial C3/CR3 mediates synapse elimination when challenged with oligomeric Aβ ([@B84]). More specifically, they found that C1q is upregulated into synapse early in J20 mice and that Aβ oligomers increase C1q and microglia phagocytic activity. This resulted in synapse elimination by microglia, a process which is lost in CR3 KO mice. This study proposes a model in which C1q and oligomer Aβ would activate the complement cascade to drive synapse elimination through microglial CR3.

Eat Me and Eat Myself {#S2.SS3}
---------------------

Autophagy and phagocytosis are cellular degradation processes, necessary to degrade additional or damaged particles in lysosomes. These processes, ensured by a large enzymatic degradation system, are dysregulated during aging and are of particular importance during AD, as shown with the autophagy failure and the increase of autophagosomes in AD patients ([@B134]). Moreover, lysosomal acidification and autophagy are disrupted by Alzheimer-related PS1 mutation ([@B109]). Numerous studies demonstrate that microglial Aβ phagocytosis contribute to degeneration by triggering NLRP3 and lysosomal cathepsin-B that subsequently results in maturation and release of IL-1β ([@B67]). Cellular degradation processes could thus, by differently modulating the inflammasome, present opposite effects. It could be protective in normal physiological states and during the premature state of the pathology, and detrimental during chronic and late phases of diseases.

Loss of Homeostatic Functions in Reactive Microglia {#S3}
===================================================

Although the majority of the studies concentrate on the microglial reactivity-acquired functions and assess their contribution to neurodegeneration, loss of key homeostatic functions may also be detrimental to neuronal functions and may contribute to the detrimental effects of microglia reaction. In the following part, we are reviewing few key microglial functions that are compromised in AD ([Figure 1](#F1){ref-type="fig"}, bottom part).

Consequences of CX3CL1/CX3CR1 Signaling Loss in AD {#S3.SS1}
--------------------------------------------------

In brain, the CX3CR1 receptor is predominantly expressed in microglia. Its ligand is the secreted soluble form of fractalkine, also named CX3CL1, and is constitutively expressed by neurons. CX3CL1 exerts an inhibitory signal, maintaining microglia in a resting state. CX3CL1-CX3CR1 is a critical signaling pathway during development as shown by the delay of glutamatergic synapse maturation ([@B139]; [@B85]) and functional consequences in adult synapses ([@B11]) in CX3CR1^--/--^ mice. Age is also a decisive factor in the regulation of CX3CR1 expression as LPS challenge is responsible for a more pronounced impairment of CX3CR1 expression in aged compared to young rats ([@B114]).

The roles of CX3CL1/CX3CR1 communication during neuroinflammation are still subject to debate since CX3CR1 deletion effects differ depending on the challenge. In CX3CR1^--/--^ mice and in both PD and ALS models, [@B26] demonstrated an extensive neuronal loss due to an alteration of cytokines production. CX3CR1 decrease is also observed in AD models. In neurodegenerative conditions, this disruption is associated with a strong microglial toxicity and an aggravation of the pathology ([@B95]). The involvement of the CX3CL1/CX3CR1 signaling pathway in AD is confirmed by an increase in the plasmatic concentration of CX3CL1 in AD and MCI patients compared to healthy control subjects ([@B99]). However, the role of this pathway might be more complex as CX3CR1 deletion was shown to prevent neuronal loss in 3 × Tg AD mice ([@B54]) but worsen cellular and behavioral deficits in hAPP-J20 mice ([@B31]).

All these data point out to critical roles for CX3CL1--CX3CR1 signaling during neurodegenerative diseases, including AD, but also demonstrate that its complex spectrum of responses may depend on the genetic model of the disease.

The Yet Unresolved Role of P2Y12 Down-Regulation in AD {#S3.SS2}
------------------------------------------------------

In physiological conditions, P2Y12 receptor is involved in chemotaxis and mice lacking this receptor showed altered microglia migration and polarization ([@B74]). *P2ry12* was identified as a unique microglia gene in the CNS ([@B24]). It is one of the most highly expressed genes in microglia and is downregulated in reactive microglia ([@B74]). Consequently, *P2ry12* gene expression levels have been proposed to be a marker of the homeostatic microglial signature ([@B24]). In agreement, in AD transgenic mouse model, microglia located at proximity of amyloid plaques do not express P2Y12R whereas the receptor is observed in plaque-distant ones ([@B24]; [@B88]). Similar findings have also been reported in human AD patients ([@B154]; [@B127]). However, so far, the consequences of this down-regulation for microglia functions are unknown and merit further attention.

Most Studied Microglial Molecular Targets in AD {#S4}
===============================================

In the past years, genome-wide association studies (GWAS) identified over 25 genetic loci that robustly associate with risk of late onset Alzheimer disease (LOAD); many of these, relate to neuroinflammation and are preferentially or exclusively expressed in microglial cells, implicating microglia reaction as not only a consequence of Alzheimer's but likely also a cause. In this section, we are reviewing the current knowledge regarding the roles of the most studied genes in this context.

APOE: Beyond Aβ Modulation, a Microglia-Function Modifier {#S4.SS1}
---------------------------------------------------------

The ε4 isoform of the Apolipoprotein E (APOE) represents a common genetic variant associated with AD and is the most significant known risk factor. APOE is an apolipoprotein implicated in cholesterol and lipid transfer between cells. In the brain, it is produced mainly by astrocytes, but also by microglia and to a lesser extent by neurons. In humans, APOE is found in three main isoforms: ε2, ε3, and ε4. The APOE-ε4 isoform represents the most significant risk factor for LOAD: the presence of one APOE-ε4 copy increases the risk of developing LOAD by three-fold whereas two APOE-ε4 copies lead to a nine-fold increase ([@B34]). On the opposite, individuals carrying the rare ε2 variant are less likely to develop AD and the most common APOE-ε3 isoform is thought to be neutral ([@B164]). How APOE isoforms affect the onset and development of AD remains unclear. Based on the early-described interaction between APOE and Aβ, studies mainly focused on the effects of APOE on amyloid load and oligomerization, which was shown to be isoforms-dependent ([@B172]; [@B130]; [@B73]). Thus, APOE-ε4 patients have more Aβ plaques and oligomers than ε3 carriers ([@B159]; [@B179]; [@B73]; [@B100]), and mouse models expressing human APOE isoforms mimics the isoform-dependent modifications on Aβ deposits ([@B46]; [@B86]; [@B204]). It was also reported that APOE can also influence Aβ clearance ([@B39]; [@B28]), however, APOE-knockdown mice develop less Aβ deposits ([@B83]; [@B46]).

Little is known regarding the microglial role of APOE. Early post-mortem studies in humans found a higher number of reactive microglia in APOE-ε4 carriers compared to APOE-ε3 ([@B44]), and recently [@B128] found that APOE-ε4 allele was strongly associated with reactive microglia. Studies using mouse models expressing human isoforms also showed increased microgliosis in APOE-ε4 expressing mice compared to APOE-ε3 ([@B13]; [@B148]). Overall, these studies highlight a relation between APOE isoforms and reactive microglia. Evidences have also been pointing out a role of APOE in inflammatory processes ([@B113]; [@B177]). Thus, APOE is up-regulated in disease-associated microglia (DAMs) and modulates transcription of homeostatic and inflammatory factors ([@B102]). Moreover, APOE modifies inflammatory response in an isoform manner; APOE-ε4 expressing mice releasing more pro-inflammatory cytokines than APOE-ε3 ([@B65]; [@B192]; [@B208]). However, the concept of APOE triggering more pro-inflammatory response has been challenged since APOE in the presence of Aβ can induce a decrease in pro-inflammatory cytokine release ([@B65]), indicating a more complex link between APOE, Aβ and glial cells. Overall, APOE is undoubtedly implicated in LOAD through Aβ aggregation and clearance but also by modulating microglia activation and cytokine release. However, additional studies are needed to explore these processes.

TREM2, the Well-Known Risk Factor With Unclarified Roles {#S4.SS2}
--------------------------------------------------------

Aside from APOE, the other major well-studied gene associated with LOAD is the Triggering receptor expressed on myeloid cells 2 (TREM2). Indeed, GWAS studies identified several rare Trem2 gene variants associated with LOAD ([@B63]; [@B91]). Among them, the rs75932628 variant, which causes the loss-of-function R47H mutation, showed significant association with AD and suggests a protective role for TREM2 activation pathway in AD ([@B63]; [@B92]). TREM2 is a cell surface receptor expressed in myeloid cells, including microglia ([@B160]; [@B97]) and was shown to modulate inflammation ([@B142]), phagocytosis ([@B175]) and chemokine secretion ([@B19]; [@B165]). How TREM2 affect AD is currently not well understood but TREM2 is increased in APP/PS1 hippocampus and cortices ([@B89]) and its expression increases with age ([@B88]). Moreover, TREM2 expression is increased in plaque-associated microglia ([@B51]; [@B63]), and modulating TREM2 expression can reprogram microglia response ([@B102]; [@B107]). In particular, Keren-Shaul et al. demonstrated that TREM2 is required for a complete activation of DAMs ([@B95]), pointing out a major role of TREM2 in those cells.

Most of the studies on TREM2 in AD relate to microglia-mediated Aβ phagocytosis, however, they do not all agree on whether it has beneficial or detrimental effects. Indeed, [@B183] found no change in amyloid burden in 3-month-old TREM2-heterozygous APP-21 mice whereas [@B88] showed reduced 6E10 staining in 4-month-old TREM2 deficient APP/PS1 mice. On the opposite, [@B196] suggested using 8-month-old 5xFAD mice, that TREM2 deficiency would be detrimental as it increases hippocampal Aβ peptide. Similarly, [@B89] showed, *in vitro*, that TREM2 facilitates Aβ 1-42 phagocytosis and, *in vivo*, that TREM2 overexpression reduces plaque density in the cortex and hippocampus of APP/PS1 mice. Altogether, these different studies suggest a complex role of TREM2 on Aβ and suggest an age- or stage-dependent effect.

Contradictory results have also been found in TREM2-dependent inflammatory response. [@B88] showed that TREM2 deficiency in APP/PS1 mice reduces the pro-inflammatory response. On the contrary, in *in vitro* studies, TREM2 overexpression was shown to reduce - while TREM2 deficiency increases - pro-inflammatory cytokine production ([@B175]; [@B89]). Therefore, further studies are required to clarify how TREM2 influences inflammatory response.

Despite discrepancies found in TREM2 implication in inflammatory response and Aβ deposition, it is of agreement that TREM2 deficiency causes a decrease in Aβ-associated microglia ([@B88]; [@B196]; [@B205]). Altogether, those studies show TREM2 implication in AD by modulating inflammatory processes and Aβ deposition. Moreover, several studies found that Aβ binds to TREM2 and that this interaction can modulate microglia functions such as proliferation, Aβ degradation and inflammatory response ([@B206]). Interestingly, a link between TREM2 and APOE has recently been highlighted suggesting that TREM2 modulates APOE expression and signaling ([@B102]; [@B140]).

Many studies aim to decipher the role of TREM2 in AD. However, current studies mainly used TREM2 overexpression or knockout although it might be relevant to also study TREM2 variants.

Other AD Risk Factors {#S4.SS3}
---------------------

Alzheimer disease-related GWAS have identified many other microglia genes as potential risk factors in AD. This includes genes such as *Cd33*, *Cr1*, or *Abca7*, which have been implicated in phagocytosis ([@B190]). Additionally, CD33 was shown to inhibit Aβ clearance whereas CR1 is part of the complement pathway that helps eliminating Aβ plaques. Various SNPs of CD33 have been found: the rs3826656 and rs3865444 variants are associated with LOAD whereas the rs3865444 variant confers protection ([@B124]). Overall, more than 25 microglia genes have been highlighted by GWAS studies ([@B187]). Their contribution to AD pathogenesis is yet unknown and merit scientists' attention as they tend to be more common genetic variants.

Emerging Microglial Targets in AD {#S5}
=================================

Emerging microglial targets are highlighted in [Figure 2](#F2){ref-type="fig"}.

![Schematic representation of the current hot topics and emerging microglial targets in AD physiopathology studied in this review. Microglia is represented in green and either with a reactive shape associated to amyloid-β deposit in purple or in the parenchyma with an homeostatic shape, away from Aβ.](fnagi-11-00233-g002){#F2}

Purinergic Signaling {#S5.SS1}
--------------------

Of the many mechanisms implicated in microglial functions, purinergic signaling is one worth mentioning. Indeed, microglial purinergic receptors are known to modulate several processes including phagocytosis, chemotaxis and cytokine release ([@B1]; [@B25]). Purinergic receptors are divided into two super families: P1 receptors respond to adenosine whereas P2 respond to ADP and ATP. Purinergic receptors are widely expressed in several CNS cell types including microglia ([@B24]), and both ionotropic P2X and metabotropic P2Y receptors have been implicated in neurological diseases including AD ([@B23]).

Of the G protein-coupled P2Y receptors, P2Y6R, 12, and 13 are the three most investigated subtypes expressed in microglia ([@B25]). In AD, the most studied is P2Y12 receptor which plays important role in homeostatic microglia and whose role is described above (see section "Loss of Homeostatic Functions in Reactive Microglia"). As for the other P2YRs, P2Y6R might be implicated in amyloid phagocytosis as [@B198] demonstrate an impaired P2Y6R-dependent phagocytosis mechanism in 9-month-old 5xFAD mice. Although P2Y2R expression in microglia seems very low ([@B25]), studies have also investigate its implication in AD. *In vitro*, Aβ treatment of primary microglia induces an increase of P2Y2R expression and Aβ-treated P2Y2R^--/--^ microglia showed loss of motility and altered ATP/UDP-triggered Aβ uptake ([@B98]) suggesting that P2Y2R up-regulation enhances microglia-dependent Aβ degradation. Interestingly, P2Y2R expression is up-regulated in 10 weeks old TgCRND8 AD mouse models and P2Y2R heterozygous mice showed accelerated pathology compared to wild-type mice ([@B7]). In contradiction with data from the TgCRND8 mice but supporting the idea of P2Y2R displaying protective effect, data demonstrate a downregulation of P2Y2R in parietal cortex of AD patients ([@B104]). Discrepancies between mice and human P2Y2R expression regulation may be explained by the stage at which the studies were conducted. Altogether, these results suggest a protective role of P2Y2R signaling in the context of AD.

The other major P2 receptors are the ATP-gated ion channels P2X receptors. There are seven P2XR subunits whose assembly in trimers forms cation-permeable channels that are widely expressed in the CNS. To date, P2X4R and P2X7R are the only P2XRs pertinently characterized in microglia. P2X7 is the most studied in AD context because of its well-established pro-inflammatory role, being a key step in the NLRP3 inflammasome activation leading to IL-1β release ([@B16]; [@B4]). P2X7R is up-regulated in AD patient brains ([@B123]; [@B118]) and administration of Aβ peptide in rat hippocampus increases P2X7R expression ([@B123]). Moreover, downregulating or blocking P2X7R decreases pro-inflammatory cytokines release in microglia cell cultures stimulated by ATP and Aβ ([@B132]). On the other hand, [@B118] demonstrate that P2X7R deficiency ameliorates cognitive functions and reduces amyloid load without altering IL-1β level. This set of data suggest a pro-inflammatory role of P2X7R in AD. Lastly, the C489T polymorphism of P2X7R, which causes a loss of function, was found to be less frequent in AD patients, supporting a potential contribution of P2X7R in AD pathogenesis ([@B155]).

Another highly expressed P2X receptor in reactive microglia is P2X4R. P2X4R are highly up-regulated upon microglia activation and have been implicated in neurological disorders and inflammatory processes ([@B174]). Although P2X4R is decreased in AD brain patients and neuronal P2X4R seems to modulate Aβ-induced neuronal death ([@B184]), no work has yet been performed on microglial P2X4R in AD.

The third main purinergic receptor family is that of adenosine P1Rs, which comprises A1, A2a, A2B, and A3 receptors. P1R are G protein-coupled receptors abundantly expressed in the CNS and all P1 subtypes are expressed in microglia. A1 and A2a receptor expressions have been found to be dysregulated in post-mortem tissues from AD patients ([@B45]), thus suggesting that P1 receptors might be implicated in AD. However, to date, not much is known regarding the contribution of microglial P1 signaling in the context of AD.

Overall, those few studies suggest the implication of microglia purinergic receptors in AD through different processes such as inflammation or phagocytosis. However, since purinergic receptors are expressed in all neural cell types incriminated in AD, more specific tools such as cell-specific KO models are required to decipher the roles of microglial purinergic signaling.

Microglial Calcium Signaling, a Poorly Studied Messenger in AD {#S5.SS2}
--------------------------------------------------------------

Calcium signaling is a key second messenger in almost all cell type and is essential for the normal CNS functioning. Many microglia functions are mediated by Ca^2+^ ([@B121]; [@B48]). In particular, microglia reaction is accompanied with intracellular calcium increase, a process that is required to induce cytokines and chemokines release ([@B80]).

Calcium signaling dysregulation in AD has been widely studied in neurons ([@B180]), but very little is known about calcium signaling in microglia in the context of AD. In an early study, [@B33] demonstrated that stimulation of cultured microglia with Aβ~25--35~ peptide results in a transient increase in intracellular \[Ca^2+^\]. This calcium is released from intracellular store and leads to microglia activation and neurotoxic factors production. More recently, McLarnon et al. showed that cultured microglia from AD patients have higher basal Ca^2+^ level but lower amplitude and longer-lasting ATP-induced calcium response with respect to that measured in microglia from non-demented individuals, thus suggesting that calcium signaling is impaired in microglia from AD patients ([@B122]).

Altered P2YR-dependent calcium signaling has been observed in plaque-associated microglia in AD mouse models whereas plaque-distant microglia showed similar Ca^2+^ activity than matched controls ([@B20]). As calcium mediates many microglial functions, it might be interesting to further investigate microglia calcium signaling in the context of AD. Particularly since some purinergic receptors are likely implicated in AD, it might be worth studying whether calcium signaling dysregulation involves purinergic signaling impairment.

Microglia in Alzheimer Disease: Current Hot Topics {#S6}
==================================================

The involvement of microglia in AD is a relatively new area of research, but it is growing at a fast pace. In addition to the pathways described above, new areas of investigation are emerging or revisited based on our current knowledge of microglial functions. In the following part, we highlight few current hot topics ([Figure 2](#F2){ref-type="fig"}). These new areas of research will help to increase our understanding of AD pathogenesis, and may, on a longer term, help to better stratify the patients and to design tailored therapeutic strategies.

Sexual Dimorphism, a Key Factor to Design Efficient Therapeutic Strategies {#S6.SS1}
--------------------------------------------------------------------------

The impact of sexual dimorphism in biology is a hot topic, and AD research makes no exception. Indeed, AD prevalence is two-fold higher in women ([@B75]), and women suffering from AD display specific cognitive alterations, biomarker patterns or risk factors susceptibility ([@B49]). This sex effect was, at first, thought to be due to higher longevity but recent reports show that it is clearly not the only explanation ([@B191]). The involvement of sex is still a subject of intense debate and biological mechanisms involved in human pathology are still controversial. Because most AD pre-clinical studies use either males or females, but rarely both, the cellular and molecular mechanisms involved in AD sexual dimorphism are still poorly understood. Yet, the few studies comparing the influence of sexual dimorphism in AD mouse models, all agree on a sooner precocious and stronger AD phenotype in females ([Table 1](#T1){ref-type="table"}). Sex-based effects are observed in different AD mouse models, both at behavioral and histological levels. Globally, cognitive alterations in females appear at younger ages and remain stronger than in males ([@B32]; [@B27]; [@B56]; [@B201]). Whatever brain areas, models and ages, females display more amyloid plaques and higher amount of soluble Aβ ([@B195]; [@B27]; [@B56]; [@B14]; [@B87]; [@B90]; [@B201]). Furthermore, in late stages, Tau phosphorylation levels and number of Phospho-Tau positive cells are higher in females ([@B32]). Synaptic and neuronal degeneration processes seem also to be stronger in aged females ([@B90]). Relative to neuroinflammation, glial cells from old female AD mice present stronger reactive states compared to males and are associated with higher levels of pro-inflammatory factors ([@B90]; [@B201]). While sex effects are clearly established in both AD mice and patients, it remains unknown whether these modifications are due to systemic/hormonal effects or whether it also exists at the cellular level.

###### 

Impact of sexual dimorphism on AD pathophyiology in various mice models.

  **AD mice model**          **Age**          **Brain area**     **Studied parameter (readout)**                                                  **Sex influence**   **References**
  -------------------------- ---------------- ------------------ -------------------------------------------------------------------------------- ------------------- ----------------------
  **Behavior studies**                                                                                                                                                
  3xTg                       6--9 mo          --                 MWM learning deficit                                                             ♀ only              [@B32]
                             15mo             --                 MWM learning deficit                                                             ♀ = ♂               [@B32]
                             2--6--9--15mo    --                 NOR                                                                              ♀ = ♂               [@B32]
                             12mo             --                 MWM retention task                                                               ♀ \< ♂              [@B201]
                             12--14mo         --                 Spontaneous alternation                                                          ♀ \< ♂              Carroll et al., 2011
  **Amyloid beta cascade**                                                                                                                                            
  3xTg                       2--6--12--15mo   Brain homogenate   Aβ 40/42 soluble and insoluble fractions (ELISA)                                 ♀ = ♂               [@B32]
                             6--8mo           PFCx               Plaques density (Aβ antibody)                                                    ♀ \> ♂              Carroll et al., 2011
                             12mo             SB, CA1, PFCx      Plaques density (Aβ antibody)                                                    ♀ \> ♂              Carroll et al., 2011
                             12mo             HC                 Aβ positive area (6E10 staining)                                                 ♀ \> ♂              [@B201]
  APP(swe)/PS1(de9)          4--12--17mo      HC                 Aβ 40/42 (ELISA)                                                                 ♀ \> ♂              [@B195]
                             12--17mo         HC                 Plaque area and density (W0--2 staining)                                         ♀ \> ♂              [@B195]
                             ?                HC, Cx             Plaque density (Congo Red staining)                                              ♀ \> ♂              [@B56]
                             ?                Brain homogenate   Insoluble Aβ42 (ELISA)                                                           ♀ \> ♂              [@B56]
                             ?                Brain homogenate   Soluble Aβ42 (ELISA)                                                             ♀ = ♂               [@B56]
                             ?                Brain homogenate   *Ide* (mRNA expression)                                                          ♂ \> ♀              [@B56]
                             ?                Brain homogenate   *Bace-1* (mRNA expression)                                                       ♀ \> ♂              [@B56]
                             12mo             OB, HC, NC         Plaque area and density (Congo red compared to Thioflavin-S and 6E10 staining)   ♀ \> ♂              [@B90]
                             12mo             Brain homogenate   Aβ 40/42 (Western Blot and ELISA)                                                ♀ \> ♂              [@B90]
                             18mo             HC, Cx             Plaque area (Campbell-Switzer Silver staining)                                   ♀ \> ♂              [@B87]
  **Tau load**                                                                                                                                                        
  3xTg                       6mo              HC                 Tau positive region (HT7 antibody)                                               ♀ = ♂               [@B32]
                             12mo             HC                 Number of P-Tau positive neurons and P-Tau area (pT231-Tau antibody)             ♀ \> ♂              [@B201]
  APPswe/PS1de9              12mo             CA1, CA3, NC       P-Tau positive area (IHC) and P-Tau quantity (WB)                                ♀ \> ♂              [@B90]
  **Inflammation**                                                                                                                                                    
  3xTg                       12mo             HC                 IBA1 and GFAP positive area                                                      ♀ \> ♂              [@B201]
  APPswe/PS1de9              12mo             Brain homogenate   TNF, IFN and Il-1β protein levels (ELISA)                                        ♀ \> ♂              [@B90]
                             12mo             OB, HC, NC         IBA1 and GFAP positive area                                                      ♀ \> ♂              [@B90]
                             12mo             HC, NC             Caspase-3 positive neurons                                                       ♀ \> ♂              [@B90]
  **Neurodegeneration**                                                                                                                                               
  APPswe/PS1de9              12mo             CA1, CA3, NC       Number of neurons                                                                ♂ \> ♀              [@B90]
                             12mo             Brain homogenate   Synaptic proteins expression level                                               ♂ \> ♀              [@B90]
                             10mo             Whole Brain        White matter, axonal and myelinated fibers volumes                               ♀ \> ♂              [@B207]
  **Comorbidity**                                                                                                                                                     
  APPswe/PS1de9              12mo             Whole Brain        Microhemorrage number                                                            ♀ \> ♂              [@B90]

This table is a non exhaustive compilation of the literature concerning AD sexual dimorphism. NC for Neocortex, PFCx for PreFrontalCortex, HC for Hippocampus, SB for Subiculum, OB for Olfactory Bulb, MWM for Morris Water Maze, IDE for Insulin Degrading Enzyme, ? for missing data.

A growing number of studies highlights the impact of sexual dimorphism on microglia shape and functions ([Table 2](#T2){ref-type="table"}). Many sex mediated effects on microglia have been demonstrated. They seem to be highly dependent on age and brain region: (1) in both mice and rats, adult males show higher microglia densities ([@B64]; [@B141]); (2) adult females microglia also display higher proportion of cells with long and thick processes while male microglia have larger soma ([@B162]; [@B64]; [@B197]). These differences may indicate that adult female microglia are in a more homeostatic state while males display a more reactive state. Functional differences are also observed, with microglia from male brain displaying higher migration rates while female's present stronger phagocytic activity related to higher expression of phagocytosis associated genes ([@B131]; [@B202]). RNA sequencing also revealed a more protective transcriptomic profile for female microglia while male microglia displayed a more inflammatory phenotype ([@B189]). A recent study also reports a sex impact on microglial electrical properties, suggesting that sex may affect microglia secretory profile, a property that can directly influence inflammatory response abilities ([@B64]). It was initially thought that microglia sex differences depend from circulating sexual hormones ([@B133]), but this view was recently challenged as it was shown that female microglia retain their protective properties when transplanted in males brain ([@B189]).

###### 

Impact of sexual dimorphism on microglial shape and function.

  **Parameter**                             **Read out**                                               **Brain area/cellular model**                                                  **Age**       **Sex influence**   **References**
  ----------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------ ------------- ------------------- ----------------
  **Microglia density**                                                                                                                                                                                                 
  Microglia density                         IBA1 positive cells                                        Hippocampus                                                                    P21           ♂ \> ♀              [@B64]
                                                                                                       Amygdala                                                                       P21           ♀ \> ♂              
                                                                                                       Cx, HC, and Amygdala                                                           13w           ♂ \> ♀              
                                                                                                       HC, Amygdala, and Striatum                                                     3mo           ♂ \> ♀              [@B141]
  **Shape**                                                                                                                                                                                                             
  Microglial compartment volume             IBA1 and CD68 staining                                     CA1                                                                            P8            ♀ \> ♂              [@B197]
                                                                                                                                                                                      P28           ♂ \> ♀              
                                            Soma size                                                  Cx, HC, and Amygdala                                                           13w           ♂ \> ♀              [@B64]
  Microglia ramification complexicity       IBA1 positive cells: Ameboid                               CA3, Dentate Gyrus, and Amygdala                                               P0            ♀ \> ♂              [@B162]
                                                                                                       CA1, CA3, Dentate Gyrus, Parietal Cortex, and Amygdala                         P4            ♂ \> ♀              
                                            IBA1 positive cells: Ramified (thick and long processes)   CA3, Dentate Gyrus, Parietal Cortex, and Amygdala                              P30 and P60   ♀ \> ♂              
  **Function**                                                                                                                                                                                                          
  Cell migration                            Transwell migration                                        Primary microglia culture                                                      P0 to P2      ♂ \> ♀              [@B202]
  Phagocytosis                              Phagocytic cup (CD68+, Dapi+)                              HC                                                                             Neo-natal     ♀ \> ♂              [@B131]
                                            Latex beads                                                Acute cortical and hippocampal slices                                          13w           ♀ = ♂               [@B64]
                                            Fluorescent beads                                          Primary microglia culture                                                      P0 to P2      ♀ \> ♂              [@B202]
  Electrophysiological properties           Baseline inward and outward conductance                    Microglia located in layers 2--6 of the somatosensory cortex in acute slices   N/A           ♂ \> ♀              [@B64]
                                            Resting membrane potential                                                                                                                N/A           ♂ \> ♀              
  Inflammatory profile (protein level)      Il-10                                                      Cx and HC                                                                      P60           ♀ = ♂               [@B162]
                                            Il-1b                                                      Cx and HC                                                                      P60           ♀ \> ♂              
  Inflammatory profile. (gene expression)   Il-10, Il1r1, Il1f1 genes                                  Cx and HC                                                                      P0, P4, P60   ♀ \> ♂              [@B162]
                                            RNASeq                                                     Isolated microglia                                                             3mo           ♀: protective       [@B189]
                                                                                                                                                                                                    ♂: Inflammatory     

This table is a non exhaustive compilation of the literature concerning microglial sexual dimorphism. Cx for Cortex, HC for Hippocampus, N/A for missing data.

Thus, although the molecular pathways involved in this microglial sexualization remain largely unknown, the current data suggest that, at least in adulthood, female microglia are in a more homeostatic and protective state. In the context of AD, it could be speculated that female microglia committed to homeostatic functions would need longer time exposure or stronger stimuli to polarize their shape and functions to answer correctly to harmful stimuli. Additionally, when they finally react to Aβ, they will change their local environment from a low- to a high-inflammatory environment. This drastic change could lead to more harmful effects on microglia themselves but also on all other surrounding cells and may explain why female are more likely to develop the pathology.

Although the effect of sex on microglial functions has been implicated in various CNS pathologies ([@B169]; [@B30]; [@B94]; [@B117]; [@B178]), further studies are needed to understand the impact of microglial sexual dimorphism in AD initiation and progression and to which extend it relies to sex disbalance in AD. Whether sexual dimorphism mechanisms are similar in human and animal models also need to be clarified.

Microglial Diversity Is Both a Challenge and an Opportunity {#S6.SS2}
-----------------------------------------------------------

Microglia cell diversity has been recognized since their first description by Pio del Rio-Hortega in 1919 ([@B166]), who reported the existence of different morphological microglia phenotypes in the human brain. He also established that microglia morphology is considerably altered in disease conditions, introducing the concept that microglia tightly adapt to their local environment. More recent functional, morphological, immunohistochemical, and medium throughput analyses of microglia in pathological conditions also pointed out to the existence of a diversity of reactive phenotypes ([@B69]; [@B147]; [@B96]). In this respect, several semi-automated tools are now available to enable the identification of phenotypically distinct microglial cell subpopulations ([@B194]; [@B186]; [@B152]).

In the last decade, the development of high throughput transcriptomic approaches combined with improved cell purification techniques helped refine our understanding of the molecular diversity of microglia both in physiological ([@B60]) and pathophysiological conditions ([@B78]; [@B82]; [@B170]; [@B42]). They established that microglia cannot be categorized in a discrete number of physiological and pathological states. However, the breakthrough in the appreciation of the microglia diversity arose from the emergence of single-cell high throughput approaches. In particular single-cell RNAseq (scRNA-seq) enables investigating the diversity at cellular resolution and allows a detailed examination of cell states diversity and changes that are reflective of those *in vivo* ([@B115]).

Two very recent scRNA-seq studies established the spatial and temporal diversity of microglia during the mouse development, and in either neurodegenerative or inflammatory conditions ([@B68]; [@B120]). These studies, together with more focused previous ones, ([@B95]; [@B52]) established that different microglia subpopulations co-exist at a given physiological or pathological state. Such heterogeneity within the microglia cell population represents both a challenge and an opportunity: the existence of distinct subpopulations supports the design of specific treatments targeting specific subpopulations with the aims of either promoting the beneficial subpopulations and/or hampering the deleterious ones.

What about microglia diversity in AD? It is known for years that AD brains exhibit at least two very distinct morphological microglia phenotypes: cells associated to the amyloid plaques display a "reactive"/amoeboid-like phenotype whereas those present in the rest of the parenchyma have a homeostatic-like morphology ([@B101]). As a mark of the importance of this diversity, it was shown that transcripts up-regulated in microglia isolated from AD mice were more highly expressed in tissues isolated in the vicinity of amyloid plaques compared to those distant from plaques ([@B137]). This suggested that microglia associated to plaques activate specific signaling pathways and functions. Using scRNA-seq of sorted 5xFAD mouse brain immune cells, [@B95] identified three distinct subtypes of microglia, including DAMs whose relative abundance increases with disease progression and which are preferentially located around amyloid plaques. The translational relevance of the DAMs was confirmed in human postmortem brains in which specific DAM markers are expressed in a subset of microglia in AD patients, but not in control subjects. More recently, in the knock-in APP^NLFG^ AD mouse model ([@B149]; [@B151]) identified activated- and interferon response microglia (ARM and IRM, respectively). ARMs partly overlap with DAMs, but by applying cell trajectory inference methods, these last authors demonstrated that ARMs were not solely present in disease conditions and are part of the normal brain aging process. However, many unresolved questions remain regarding the functional significance of this diversity. In particular, when it arises during AD progression and whether it is already present at the prodromal stages of the disease. With progress of both technology and analytic methods, it is now feasible to get a deeper understanding of the microglia diversity across AD progression. Identification of specific, potentially small in size, microglia subpopulations may have important implications for translational applications. Identification of factors released by these subpopulations and that can diffuse to the CSF may lead to the identification of new biomarkers. Additionally, identification of specific subpopulations will help discover new pathways and functions that contribute to the disease progression and may lead to the development of more specific functional positron emission tomography (PET) tracers. Deciphering, whether these subpopulations have beneficial, neutral or detrimental effects on brain cells, including neurons, will open the way for the design innovative disease-modifying therapeutic strategies.

Studying AD at Early Stages to Identify Early Biomarkers {#S6.SS3}
--------------------------------------------------------

After years of unsuccessful clinical trials, scientists are now realizing that AD is a pathology we may want to prevent (or stop) rather than to cure. This is calling for the identification of early diagnostic biomarkers, which are sorely lacking to help prodromal diagnostic, or design innovative disease-modifying therapeutic strategies. Although AD early stages are still less studied, increasing number of studies are now focusing on the prodromal phases to unravel early dysregulations.

Because one of microglia's main role is to sense their environment and to react to danger, they are likely to play key roles in initial brain response to AD-driven changes. In agreement, a recent PET and magnetic resonance imaging (MRI) based study showed that AD patients have a first microglial activation peak before they display any other hallmarks of the pathology, suggesting that microglial dysfunction is critically involved in AD initiation ([@B47]). The involvement of microglia in AD initiation stages raises the question of which microglial targets could be modulated at an early stage to slow down the progression of the disease.

*Extracellular vesicles* (EVs) are a family of small membrane vesicles, which includes exosomes and microvesicles (MVs), transporting various types of molecules. In the recent years, EVs have emerged as a new mean of communication between cells. Microglia abilities to secrete EVs and MVs are part of their essential inflammatory functions. In the Aβ phagocytosis process, overloaded microglia can release Aβ-containing small secretory vesicles ([@B93]), as well as Tau or P-Tau through exosomes ([@B153]; [@B9]). Accordingly, the levels of myeloid MVs detected in the CSF of MCI or early stage AD patients, is correlated with the extent of their white matter damage ([@B5]). Microglial EVs may thus be regarded as a possible mean to spread the pathology during early stages. Interestingly, because they are secreted and can access first the CSF compartment and then the blood, microglial EVs may represent valuable diagnosis tools ([@B181]).

*Oxidative stress* is known as a necessary but potentially harmful process. In response to fibrillary Aβ, reactive microglia produce free radicals, notably superoxide via the NADPH oxidase (NOX) ([@B71]). Moreover, NOX activity is increased in MCI patients compared to controls ([@B21]). These findings open the way for using NOX activity as the marker of early microglia reaction in AD. Interfering with NOX activity through specific compounds may also provide a mean to slow down the pathology ([@B43]).

*Iron* is an important metal implicated in vital biological processes. However, intracellular iron overload can lead to neuronal degeneration ([@B203]). Microglia are able to interact, transport and metabolize iron. When they secrete pro-inflammatory factors, microglia can stimulate neuronal iron uptake leading to an increase in neurodegeneration ([@B203]). Interestingly, patients with specific iron overload disorder are subject to earlier onset of AD, suggesting that iron may be involved in the initiation steps of the pathology. Moreover, iron chelation seems to be beneficial to AD patients. Further work is needed to understand the early implication of microglial iron regulations in AD ([@B136]).

Barriers to Discoveries {#S7}
=======================

Although fundamental knowledge is of importance, the ultimate goal of characterizing cells functions and dysfunctions in physiological and pathological conditions is to design efficient therapeutic strategies with clinical benefit. Understanding the complexity of Alzheimer's disease is one of the XXIth century challenges. To do so we mainly rely on animal models that mimic the symptoms of the pathology (amyloid deposits, hyperphosphorylated tau, cognitive alterations, etc.). However, so far, the results generated from these models have generally failed to translate to clinic, and only symptomatic and poorly efficient treatments exist ([@B146]). In the two following paragraphs, we explore two important factors that may have been under-estimated in AD pre-clinical research: the relevance of current AD mouse models and the immunological differences between mice and humans. These remarks do not only apply to the study of microglia' roles in AD, but are important issues to consider for the design of any preclinical studies.

Are the Current Mouse Models Tailored to Understand AD and Identify Drug Targets? {#S7.SS1}
---------------------------------------------------------------------------------

Most of the animal models are genetically engineered to overexpress human protein mutations also leading to an overexpression of their respective by-products, thus generating potential confounding factors ([@B157]). In addition, most AD models are based on familial mutations whereas early-onset familial AD is estimated to account for only 3.5% of total AD cases ([@B72]). In addition, some of these models are based on a combination of mutations that were never found in patients. Because it is the first hallmark of AD, most of the models focused on the amyloidogenic pathway ([@B157]). However, it is clear that, in humans, there is a concomitant effect of Aβ and P-Tau. To solve this issue, the 3x-Tg model is combining Aβ and Tau associated features. However, it only poorly represents the pathology in term of kinetic of appearance of the symptoms as cognitive deficits appear way too early and before any amyloid accumulation or Tau dysregulation (AlzForum^[1](#footnote1){ref-type="fn"}^). To solve these issues, new mouse-based or human-based models are created (see section "New opportunities in AD research").

To study microglia impact on AD, new models have been created by combining microglial dedicated tools with AD models ([@B207]). One of the most commonly used models is the CX3CR1^+/eGFP^ x APP/PS1 strain, in which an allele of the fractalkine receptor CX3CR1 is replaced by a GFP allowing to track microglial cells. However, to our knowledge, the impact of the CX3CR1 haplo-deficiency on AD development has not yet been thoroughly investigated. Finally, AD studies are generally conducted in old mice, when the pathology symptoms and hallmarks are well established. This stage of the pathology is probably too advanced for the identification of efficient disease modifying drugs.

Human and Mice Are Not Immunologically Similar {#S7.SS2}
----------------------------------------------

In the field of inflammation, the comprehensive study by [@B163] revealed that gene dysregulation in mouse models of severe human inflammatory conditions (endotoxemia, burns, and trauma) do not correlate with human genomic changes. This raises the question of the relevance of mouse models to study the role of immune cells in diseases, including brain disease. Several factors known to be of importance for immune functions differ between rodents and human studies. Most often, rodent models and studies use inbred strains whereas human genetic backgrounds are much more diverse. Additionally, humans are exposed to multiple diseases whereas research mouse models are raised in tightly controlled environment ([@B38]).

Functional studies investigated the response of human microglia to either endogenous (i.e., M-CSF) or exogenous (i.e., LPS) stimuli ([@B125]; [@B168]). For the most part, they show comparable results with mouse analyses, thus agreeing with two comprehensive transcriptomic studies which compared gene expression profiles in human and mouse microglia and concluded that, overall, gene expression is very similar in the two species ([@B55]; [@B59]). Of interest to brain diseases, a good correlation between human and mouse microglia in response to neurodegeneration was also observed by other authors ([@B81]; [@B95]; [@B102]).

However, notwithstanding their global resemblance, significant number of genes are differentially expressed in mouse and human microglia. In particular, specific immune genes are only expressed in human samples ([@B59]). In addition, differences in the relative expression of lineage- and signal-dependent transcription factors between mice and humans were observed ([@B82]). In line, previous studies identified several molecular pathways and signaling functions that significantly differ between mouse and human microglia. This includes proliferation, response to TGFβ1, Siglecs signaling, nitric oxide (NO) production, and response to certain drugs such as valproic acid (VPA) ([@B167]).

Of relevance to AD, Siglec-3 (CD33) that has been identified as a risk factor for AD ([@B15]) displays substantial species differences in expression patterns and ligand recognition ([@B105]). Additionally, age-related changes of immune and cognitive functions may not be correctly modeled in rodents, whose life expectancy is far less compared to humans. Accordingly, gene expression changes in aged human brain are significantly different from those in the mouse brain ([@B112]; [@B17]). In agreement, [@B55] revealed that there is a limited overlap in age-related changes in human and mouse microglia, highlighting that data obtained in aged mice should be extrapolated to the human situation with caution. Translation of results from mice to humans is also hampered by the lack of tools to precisely characterize microglial reactivity in patients: TSPO binding is so far the only way to study microglia reaction in a clinical context.

Although methods to purify, culture and experiment on human microglia have been established, access to human samples that meet the requirements of high-quality studies is limited. AD mouse models are thus undoubtedly useful to decipher the roles of specific microglial functions and signaling pathways. However, the species differences highlighted above should prompt scientists to confirm the results they obtained in mouse models on human samples.

New Opportunities in AD Research {#S8}
================================

While current models to study AD have multiple limitations, scientists are trying to generate new models with limited pitfalls. In this last part, we are reviewing new approaches currently developed. These approaches are expected to improve our knowledge on microglial functions and help bridge the gap between *in vitro* studies, rodent models and the human disease.

Promising Animal Models to Overcome Identified Pitfalls {#S8.SS1}
-------------------------------------------------------

Although mouse models present significant pitfalls, they are attractive models in preclinical studies. Indeed, they are small, easy to raise, mammals with reasonable life expectancy. They reproduce well in captivity and can be engineered and/or humanized in a relatively easy way. Furthermore, with the exponential development of a wide repertoire of mouse lines (Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease^[2](#footnote2){ref-type="fn"}^), it is possible for scientists to explore new hypotheses by combining different mouse lines. In this context and to overcome the problems associated with APP overexpression, Drs Saito and Saido developed new knock-in AD mouse models, namely the APP^NLF^ and APP^NLFG^ mice ([@B149]). In these models, mutated APP is expressed from its endogenous promoter, leading to a kinetic of appearance of the symptoms which is more comparable with human pathology ([@B150]). These models are not thoroughly characterized yet and still excludes Tau-associated dysfunctions. However, in the APP^NLF^ model, the delay before Aβ deposits appearance supports that it may represent an interesting model to study the prodromal phase of the disease.

Other models, not based on genetic modifications, have also emerged in the last decades. Compared to humans, dogs share an almost identical enzymatic machinery to process APP. Moreover, they may naturally develop an age-related cognitive dysfunction that reproduces several aspects of AD ([@B161]). With its high life span, the canine model can be useful specifically to study pathways involved in Aβ deposition and clearance in the early phases of the disease ([@B156]). To get closer to human pathology, several primate models are currently used to study AD. Depending on their phylogenetic distance to humans, they neither display the same kinetic nor kind of neurological alterations ([@B77]). Among primates, *Microcebus Murinus* also known as the gray mouse lemur, is particularly interesting ([@B18]). Indeed, they are small animals, just over the size of a mouse. They can be raised in cohorts of several individuals, and can reproduce in captivity. Along aging some individuals naturally develop an AD like pathology with Aβ plaques ([@B126]), associated with specific transcriptomic remodeling ([@B2]). Histological features also seem to be associated with cognitive alterations ([@B182]). Although we know that, at least in the spinal cord, the gray mouse lemur microglial shape and distribution is closer to human compared to mouse ([@B106]), microglia are still poorly studied in this model. Further studies are needed to investigate the involvement of microglia in this age-related AD like pathology.

Although, both dog and primate models represent interesting models, they are not so easy to use. For example, there are only few breeding centers for *Microcebus Murinus* worldwide. Those animals also need more housing space and their use is subjected to drastic ethic rules. Moreover, many of the research tools are designed on mouse genome/proteins limiting the use of these peculiar models.

hiPSCs-Derived Microglia: An Emerging Tool to Decipher the Role of Microglia in AD {#S8.SS2}
----------------------------------------------------------------------------------

To overcome species issues, microglial cell lines of human origin can be useful. They allow to study specific biological functions or functional pathways; however, they cannot reproduce the complexities of cells. This particularly true for cells which, like microglia, are highly adapted to their environment. Bone marrow-derived or blood monocytes-derived macrophages represent another source of human microglia-like cells. However, because these cells are of fundamentally different embryonic origin ([@B79]), they are likely poor models of adult microglia. Adult primary microglia can be harvested from dissociated brain area, but this process generally lead to low yields and can only sparsely be obtained for human samples. Moreover, isolation processes and culturing methods impact on gene expression pattern thus calling for caution in interpreting results based on these approaches ([@B59]).

An alternative to those issues is the development of cell reprograming methods, which offer the possibility to generate human pluripotent cell lines (hiPSCs) from healthy individuals but also from patients with specific diseases ([@B173]). Human iPSCs-derived neural cells can be produced in consistent yields. In the context of AD, iPSC-derived neurons issued from either familial AD (FAD) patients carrying mutations found in AD or sporadic AD (SAD) patients recapitulate some of the main hallmarks of the disease ([@B144]). Similarly, astrocytes derived from AD-patient iPSC show significant morphological and functional alterations, including up-regulation of inflammatory cytokines ([@B29]; [@B10]).

Human pluripotent cell lines have recently been successfully differentiated into microglia ([@B129]; [@B3]; [@B41]; [@B66]; [@B176]; [@B143]). Although there is yet no consensus protocol to obtain hiPSCs-derived microglia, all protocols follow similar steps based on this cell type ontogeny. Based on such protocol, [@B57] recently described microglial dysfunctions in hiPSCs-derived microglia from TREM2 T66M and W50C carriers, thus outlining the interest of such iPSCs approaches to decipher the role of microglia functions and dysfunctions in AD. Deciphering to which extend hiPSCs microglia derived from different patients (i.e., different SADs and/or different FAD mutations) share the same molecular and/or functional characteristics will help better understand the heterogeneity of AD, and may open the way toward the use of hiPSCs to implement personalized treatment in AD.

An important emerging concept is that, because microglia are CNS resident macrophages highly adapted to the CNS environment, a two-steps protocol is required to obtain hiPSCs-derived microglia with genuine microglial functions. In this scheme, the first step is to obtain iPSCs-derived macrophages progenitors and second to grow them in a conditioned environment, i.e., in the presence of other neural cells ([@B108]). Under such experimental settings, hiPSCs-derived microglia exhibit phenotype, gene expression profile and functional properties close to brain-isolated microglia ([@B138]; [@B176]).

Maintenance of tissue architecture is an important aspect of *in vivo* studies. Interestingly, hiPSCs derived cells can be grown in 3D cultures to model the cytoarchitecture and the connectivity of the brain while allowing *in vitro* manipulation and experimentation. Such 3D or organoids models open the way for studying human microglia under conditions that are close to physiological and physio-pathological context. Although specific pitfalls exist with such approaches, including the need to develop isogenic controls to alleviate the risk of cofounding factors due to difference in genetic backgrounds between patients and controls, there is little doubt that these approaches will be instrumental to decipher the role of microglia in the progression of AD.

Concluding Remarks {#S9}
==================

Glial cells, including microglia, have long been suspected to play a role in Alzheimer's disease but only because of their ability to react to neuronal dysfunctions (e.g., Amyloid and Tau aggregates). This neurocentric view, which considered glial cells as secondary, has been challenged recently by the results of genetic association studies identifying genetic loci associated with risk of Alzheimer's that are associated to genes preferentially or exclusively expressed in glial cells ([@B187]). This has refined our view of how Alzheimer disease initiates and progresses, and introduced new concepts and ideas for Alzheimer's pathophysiological mechanisms, both at the molecular and cellular levels.

Because of their abilities to sense and react to their environment, reactive microglia are likely playing key early roles in the disease progression and may lead to the identification of early biomarkers. Because they can drive functional changes in astrocytes ([@B111]) and crosstalk with non-neuronal immune cells ([@B40]), they also represent attractive drug targets to stop or limit the disease progression.

As reported here, the exact contribution of the different reactive microglia subtypes to AD is currently unclear and the subject of intense researches. Over the recent years, several technological breakthroughs have been achieved, allowing scientists to address new challenging questions. These technical developments now allow studying microglia roles with medium or high throughput flows, and perform fine analysis of their functions in preserved environments. A better understanding of the contribution of microglia cells to AD initiation and progression is expected to renew the interest of big pharma to re-invest in the field and will pave the way toward better designed strategies.

Many factors need to be considered, including sex, age, species, molecular diversity, health status, communication with the periphery, etc., to fully decipher the role of microglia in AD. These are undoubtedly challenging but also very exciting fields of research, which hold the promise of defining innovative therapeutic strategies and reduce the socio-economic burden of this devastating disease.
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